Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03504163 | Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] | active not recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04395079 | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | active not recruiting | Phase 2 | 9 | Jonsson Comprehensive Cancer Center |
| 1 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy(EXCALIBUR) | active not recruiting | Phase 2 | 165 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT00848289 | Genetic Susceptibility to Bladder Cancer | active not recruiting | — | 6,086 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01217931 | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | active not recruiting | Phase 2 | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03999151 | Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II) | active not recruiting | N/A | 204 | University of California, San FranciscoOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04622670 | Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer | active not recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)(KEYNOTE-B15) | active not recruiting | Phase 3 | 808 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Jul 16, 2026 | clinicaltrials |
| NCT05465941 | PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | active not recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05501054 | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | active not recruiting | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05843448 | IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 1 | 6 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder(ADAPT-BLADDER) | active not recruiting | Phase 1 / Phase 2 | 186 | Noah Hahn, M.D.OTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04267887 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06533059 | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | active not recruiting | Phase 1 | 110 | Alterome Therapeutics, Inc.INDUSTRY | 8 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT01505400 | Integrated Molecular Profiling in Advanced Cancers Trial(IMPACT) | active not recruiting | — | 3,026 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | active not recruiting | Phase 3 | 60 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT05169970 | A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer | active not recruiting | Phase 2 | 222 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05842057 | Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy(HAMMER) | active not recruiting | Phase 2 | 118 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT00868803 | Aberrant Gene Expression Prostate Carcinoma | active not recruiting | — | 5,000 | Lahey ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT04748042 | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | active not recruiting | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05024734 | Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids(GAIN-INST) | active not recruiting | Phase 2 | 31 | Roland Seiler-BlarerOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05644041 | Intravesical Gem/Doce in Patients With NMIBC | active not recruiting | Phase 2 | 31 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).(INTerpath-004) | active not recruiting | Phase 2 | 272 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Jul 13, 2026 | clinicaltrials |
| NCT07697417 | Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma(PN-ProMM) | active not recruiting | — | 406 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04830709 | Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer(SCOUT-1) | active not recruiting | — | 752 | AstraZenecaINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations(NePtune) | active not recruiting | Phase 2 | 32 | Rana McKay, MDOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06004661 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | active not recruiting | Phase 2 | 23 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 10, 2026 | clinicaltrials |
| NCT01508390 | Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate | active not recruiting | N/A | 35 | Boston Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02319837 | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 17 | Jul 9, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT01140373 | Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) | active not recruiting | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT01883297 | "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 3 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O) | active not recruiting | Phase 3 | 1,407 | AstraZenecaINDUSTRY | 20 | Jul 7, 2026 | clinicaltrials |
| NCT04624256 | Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial(GARUDA) | active not recruiting | N/A | 208 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06029998 | Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion(BORXPTEN) | active not recruiting | Phase 2 | 22 | University of UtahOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06611540 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 17, 2026source: clinicaltrials